June 1st, 2021 | 10:05 CEST
Defence Therapeutics, CureVac, BioNTech: Vaccine against cancer makes progress
Biotechnology is the map to the holy grail that needs to be found as quickly as possible for many sick people. When the pandemic broke out last year, it accelerated some developments. For example, mRNA technology, which BioNTech and CureVac had already been researching, was successfully launched as a vaccine technology. It is well known that this can be used to develop effective vaccines against coronaviruses and target diseases such as cancer. BioNTech has this option in mind and holds good cards to succeed with it. The young biotech startup Defence Therapeutics has also recently reported its first successes in the fight against cancer.
time to read: 3 minutes
|
Author:
Nico Popp
ISIN:
CA24463V1013 , NL0015436031 , US09075V1026
Table of contents:
"[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.
Author
Nico Popp
At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.
Tag cloud
Shares cloud
Defence Therapeutics: Accum™ technology brings active ingredients to the target
Defence Therapeutics specializes in targeting active ingredients, such as vaccines or drugs. To do this, the Company uses antibodies that virtually "piggyback" on certain active ingredients. The antibodies can then dock onto a cancer cell, block a receptor there, and carry the active ingredient into the respective cell. Defence Therapeutics has developed Accum™ technology to facilitate this process, enabling active ingredients to be directed even more effectively into affected cells. Specifically, this is achieved by attaching a specific amino acid chain to the antibody, which increases the cell nucleus concentration of the active ingredient used. These so-called Antibody Drug Conjugates (ADC), i.e. the combination of antibody and active ingredient, are considered promising and innovative in research.
As a second mainstay, Defence Therapeutics is developing vaccines. Since these can also be delivered more effectively to the target using ADC technology, the Company's fields of activity complement each other perfectly. Most recently, Defence Therapeutics reported the success of a pre-clinical study on mice. In this study, mice suffering from cancer were treated with the vaccine AccuVAC-D001 developed by Defence Therapeutics. In the end, 70% of the mice with established solid tumors were cured. While it is still a long way from a pre-clinical study in mice to a vaccine for humans, Defence Therapeutics shows that the dream of curing cancer is no longer a utopia. The Company expects the global market for vaccines to grow by 10.7% each year through 2027. Defence Therapeutics is well positioned to benefit from this innovative technology - either as an independent vaccine manufacturer or an acquisition target. Compared to companies like CureVac or BioNTech, the Canadian Company is still in its infancy. For investors, this can be an opportunity.
CureVac: Is there still something to come?
Latecomers have great opportunities, especially when the top dogs stumble. This is currently the case with CureVac. For months, observers have been waiting for the Corona vaccine from Tübingen to finally be launched on the market. Data on its efficacy are still awaited. In parallel, the Swabians are already working with partner Glaxo-SmithKline on a new generation of the vaccine, and this should enter clinical trials in the third quarter. But brash announcements do not yet ensure success.
In January 2020, CureVac had already made a bold announcement of its intention to develop a vaccine. At the time, the Company was ahead of its Mainz-based rival BioNTech. But BioNTech has overtaken CureVac. While the Tübingen-based Company is seen as a Company that wants to do everything very precisely, BioNTech is taking a different approach and wants to get there quickly. Since BioNTech has been approved since the end of 2020 and has already made a name for itself worldwide, the Mainz-based Company's approach must be considered the more successful. In addition, the numerous virus variants make it more difficult for CureVac to conduct clinical trials. When BioNTech was at this stage, the original type of virus was much more widespread. Today, the pandemic situation is much more complex.
BioNTech has its nose in front - Defence Therapeutics as a biotech insider tip
On the stock market, the prices of BioNTech and CureVac have been diverging since March. Since May, the difference has widened even further. The reason is clear: While CureVac is still researching, BioNTech is already earning money. In the long term, however, it cannot be ruled out that CureVac will get back on track - especially the new-generation vaccine could put the Company on the road to success. For both German biotech companies, however, it is equally true that they are already ambitiously valued. In the case of BioNTech, this valuation has a stronger fundamental basis. For investors who want to follow a trend from the very beginning, however, both shares are already unsuitable today. Defence Therapeutics could be an exciting alternative here. The Accum™ technology, designed to deliver active ingredients precisely to malignant cells, and the initial successes in developing a vaccine against cancer make investors sit up and take notice.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
